Sloan-kettering Institute for Cancer Research

Memorial Sloan Kettering Cancer Center

Sloan-kettering Institute

Academia Sinica

Malcolm A Moore

Janice L Gabrilove

Jochen Buck

Karl Welte

Karl Henry Nocka

Erich Platzer

Peter Besmer

Roland Mertelsmann

Samuel J Danishefsky

Ouathek Ouerfelli

Joan Massague

Tsann-Long Su

Te-Chang Lee

Guangli Yang

Manuel Valiente Cortes

Thordur Oskarsson

Nicolas Lecomte

Roland Mertelsm

Jae-Hung Shieh

Server A Ertem

Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymphoblastic leukemia (B-ALL)], lymphomas, small lung cell carcinoma (SCLC), sarcomas, and others.

Use of ureidomustine (BO-1055) in cancer treatment

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Migrastatins and uses thereof

Methods for inhibiting the growth of ovarian cancer cells or other serosal cancer cells are disclosed. The method involves exposing the cells to a benzylidinebenzohydrazide of formula: wherein X is carbon or nitrogen.

Treatment of ovarian cancer with benzylidenebenzohydrazides

Compositions comprising c-kit ligand, TNF-.alpha., and a hematopoietic factor are useful to promote the expansion of peripheral blood cells or the expansion and differentiation of hematopoietic progenitor cells.

Use of c-kit ligand with TNF-.alpha. and hematopoietic factors for the

Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5.times.10.sup.8 U/mg protein.

Human pluripotent hematopoietic colony stimulating factor and cell line

A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.

Growing community of inventors

Larchmont, NY, United States of America

Malcolm A Moore